Navigation Links
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
Date:5/9/2008

HOPKINTON, Mass., May 9 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a conference call on Thursday, May 15th, 2008 at 9:00am EDT to review the first quarter ending March 31, 2008 and discuss other matters related to the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

To access the conference call, please dial 877-795-3649 for domestic and 719-325-4817 international. The code for this conference call is 1073493. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the conference call and will be available through Thursday, May 29th, 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres is a trademark and Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact:

Sharon Correia - 508-497-2360 ext. 224

Alseres Pharmaceuticals, Inc.

scorreia@alseres.com

Adam Friedman - 212-981-2529 ext. 18

Adam Friedman Associates

adam@adam-friedman.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
2. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
3. Alseres Pharmaceuticals, Inc. Raises $5 Million
4. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
5. Vion Pharmaceuticals to Appeal Nasdaq Delisting
6. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
7. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
8. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
9. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... Today, True Vision Funding LLC ... formation of a new division for the purchase of sports and music entertainment ... , Clinton Portis, former Washington Redskins running back and supporter for TVF ...
(Date:3/1/2017)... ... March 01, 2017 , ... Financial Recovery Group, Inc. (FRG), is ... Nashville Summit in Nashville, Tenn. The company also is offering a special discount for ... in its 11th year, brings together the brightest minds in the healthcare industry to ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... pleased to announce the release of its 2017 update to Compass, the ... staff and physician advisors. , Suitable for standardizing both new-hire on-boarding and ...
(Date:3/1/2017)... ANGELES, CA (PRWEB) , ... March 01, 2017 , ... ... launch of her new mobile app Time & Go. , Time & Go app ... of life: career, relationships, and well-being. Efficient time management methods enable people to work ...
(Date:3/1/2017)... ... March 01, 2017 , ... “There is Comfort for the Soul”: ... the author in their all-too-brief time together, and the soul-healing comfort provided by God’s ... the creation of published author, Jerie A. Tau, a dog-loving medical professional whose work ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
(Date:3/1/2017)... 1, 2017  The Pharmaceutical Care Management Association (PCMA) ... vote to advance the nomination of Seema Verma ... Services Administrator: "The popular Medicare Part ... American health care. By offering an abundance of competing ... tools like pharmacy networks and home delivery, the program ...
(Date:3/1/2017)... -- The global  Intraoperative Neuromonitoring (IONM) market  is expected to reach ... Research, Inc. The intraoperative neuromonitoring market is anticipated to witness significant growth in ... in a wide spectrum of surgeries. Continue Reading ... ... ...
Breaking Medicine Technology: